Every Mass Tort.
Litigation intelligence.
One feed.

Bayer's $7.25 billion Roundup class settlement received preliminary approval March 4, 2026 in MDL 2741 (N.D. Cal., Judge Vince Chhabria), with a final approval hearing scheduled for July 2026. Roughly 4,500 federal cases remain active as the Supreme Court prepares to hear Durnell v. Monsanto on April 27, 2026 — a preemption challenge that could reshape the entire litigation. A plaintiff win at the Supreme Court would remove a key defense and potentially reopen claims for thousands of claimants whose cases were stayed pending the outcome.

Social media addiction bellwether proceedings in MDL 3047 (N.D. Cal., Judge Yvonne Gonzalez Rogers) are accelerating toward trial, with the first bellwether — a school district case — set for June 15, 2026, and a state AG case to follow August 6. Pretrial conferences are scheduled for March 18 and April 14, with summary judgment arguments in the AG case set for April 15. Discovery into Meta's internal algorithm documents continues and is expected to generate significant Daubert motion practice before trial.

In AFFF MDL 2873 (D.S.C.), the personal injury track has shifted toward global settlement after the October 2025 bellwether trial was vacated, with 15,220 active filings comprising 130,000+ individual and municipal plaintiffs before Judge Richard Gergel. The 3M public water supplier settlement ($10.3 billion) received final approval in April 2024, and defendants are now focused on resolving the personal injury docket through a negotiated framework rather than trial. Plaintiff leadership is pressing for a case management order establishing a path to global resolution.

Johnson & Johnson faces 67,622 claims in talc MDL 2738 (D.N.J.) following a $1.56 billion Baltimore verdict in December 2025 — the largest individual talc verdict in history — and a $966 million Los Angeles mesothelioma verdict in October 2025. J&J's third bankruptcy attempt through Red River Talc LLC was dismissed in March 2025 with no appeal, closing that avenue and returning focus to federal MDL proceedings. Bellwether trial scheduling is expected to accelerate in 2026 as J&J exhausts its procedural options.

Depo-Provera MDL 3140 (N.D. Fla., Judge M. Casey Rodgers) is at a critical juncture as Pfizer's preemption motion for summary judgment awaits ruling after oral argument in September 2025. The FDA's December 2025 approval of a meningioma warning label for Depo-Provera has significantly undermined Pfizer's preemption argument, prompting supplemental briefing and raising plaintiff attorneys' expectations for denial. A ruling against preemption would clear the way for bellwether discovery on 3,099+ pending meningioma claims.

Ozempic gastroparesis litigation in MDL 3094 (E.D. Pa., Judge Karen Marston) has grown to 3,363+ cases as of March 2026, with new filings arriving weekly and discovery into Novo Nordisk clinical trial data ongoing. The litigation remains separate from the NAION vision-loss track consolidated in MDL 3163, which has 54 cases and newly appointed leadership as of March 3, 2026. Both tracks are in early discovery with no bellwether schedule yet established.

Camp Lejeune Justice Act litigation in the Eastern District of North Carolina has reached 409,910 unique administrative claims received by DOJ and the Navy, with approximately 64,041 qualifying under the Elective Option settlement program. The government has paid roughly $530 million through the EO program to date. First bellwether trials are expected in 2026, though no specific trial dates have been set.